Human CD300a/LMIR1 Antibody

Catalog #: MAB2640 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB2640
MAB2640-SP

Detection of Human CD300a/LMIR1 by Western Blot.

1 Image

All CD300a/LMIR1 Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human CD300a/LMIR1 Antibody Summary

Species Reactivity

Human

Specificity

Detects human CD300a/LMIR1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, 100% cross‑reactivity with recombinant human LMIR2 (CMRF-35A) is observed and no cross-reactivity with recombinant human LMIR3, 4, 5, or 6 is observed.

Source

Monoclonal Rat IgG_2A Clone # 232612

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Y3 rat myeloid cell line transfected with human CD300a/LMIR1

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

Human granulocytes under non-reducing conditions only

Flow Cytometry

2.5 µg/10⁶ cells

Human whole blood

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot

View Larger

Detection of Human CD300a/LMIR1 by Western Blot. Western blot shows lysates of human granulocytes. PVDF membrane was probed with 2 µg/mL of Rat Anti-Human CD300a/LMIR1 Monoclonal Antibody (Catalog # MAB2640) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (HAF005). A specific band was detected for CD300a/LMIR1 at approximately 60 kDa (as indicated). This experiment was conducted under non-reducing conditions and using Immunoblot Buffer Group 1.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD300a/LMIR1

CD300a, also known as LMIR1 (in rodents), CMRF-35H, IRp60, CLM-8, and MAIR-I, is a 60 kDa glycoprotein member of the immunoglobulin superfamily (1). Human CD300a consists of a 163 amino acid (aa) extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane segment, and a 98 aa cytoplasmic domain that contains three immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and a non-canonical ITIM (2). Alternative splicing may generate additional isoforms that either lack the Ig-like domain or contain only the cytoplasmic domain. Within the ECD, human CD300a shares 40% and 43% aa sequence identity with mouse and rat LMIR1, respectively. In human, CD300a is expressed on peripheral blood eosinophils, mast cells, neutrophils, plasmacytoid dendritic cells, and various T cell subsets (3‑7). Antibody crosslinking of CD300a induces phosphorylation of tyrosine residues in the cytoplasmic domain. This leads to the recruitment of phosphatases SHIP, SHP-1, and SHP-2 and inhibition of NK cell, eosinophil, and mast cell activation (2, 3, 5‑7). Crosslinking of CD300a to other surface proteins such as SCF R or Fc epsilon RI on mast cells, Fc gamma RIIA on neutrophils, or CCR3 on mast cells and eosinophils inhibits downstream signaling from those receptors (5, 10‑12). CD300a crosslinking also limits the in vivo activities of these cells with a subsequent reduction of allergic inflammation symptoms (4, 11, 12).

References

Clark, G.J. et al. (2009) Trends Immunol. 30:209.
Cantoni, C. et al. (1999) Eur. J. Immunol. 29:3148.
Munitz, A. et al. (2006) Blood 107:1996.
Bachelet, I. et al. (2005) J. Immunol. 175:7989.
Alvarez, Y. et al. (2008) Mol. Immunol. 45:253.
Ju, X. et al. (2008) Blood 112:1184.
Clark, G.J. et al. (2007) J. Leukoc. Biol. 82:1126.
Kumagai, H. et al. (2003) Biochem. Biophys. Res. Commun. 307:719.
Yotsumoto, K. et al. (2003) J. Exp. Med. 198:223.
Bachelet, I. et al. (2008) J. Immunol. 180:6064.
Bachelet, I. et al. (2006) J. Allergy Clin. Immunol. 117:1314.
Munitz, A. et al. (2006) J. Allergy Clin. Immunol. 118:1082.

Entrez Gene IDs

11314 (Human); 217303 (Mouse)

Alternate Names

CD300a antigenCMRF35H9; CD300a molecule; CD300a; CLM8; CLM-8; CMRF35H leukocyte immunoglobulin-like receptor; CMRF-35H; CMRF35-H; CMRF35-H9; CMRF-35-H9CD300 antigen-like family member A; CMRF35HIRp60; CMRF35-like molecule 8; IGSF12; IGSF12NK inhibitory receptor; Immunoglobulin superfamily member 12; Inhibitory receptor protein 60; IRC1; IRC1/IRC2; IRC2; IRp60; leukocyte membrane antigen; LMIR1; MAIR-I; Mcipr1; NKRL; Pigr4